Finasteride vs minoxidil compares two established hair-loss treatments that work through different pathways. We use baseline data, physician review, and follow-up response to judge whether a treatment is doing what the plan intended. Finasteride lowers dihydrotestosterone (DHT), while topical minoxidil acts locally on the hair cycle.1,2 One small, open-label comparison favored finasteride. Separate placebo-controlled trials show that each treatment can improve hair outcomes.
Finasteride vs Minoxidil at a Glance
Finasteride targets the hormonal pathway involved in male pattern hair loss, while minoxidil acts on the follicle and hair-growth cycle. That difference affects the route, timeline, side effects, and follow-up questions your prescriber will weigh.
The timelines below help set the first review point. They are not deadlines for declaring treatment success or failure. Your prescriber uses the expected timeline to judge whether more observation, a route change, or a different plan makes sense.
| Drug | What It Is / Route | FDA Status for Hair Loss | What the Trial Evidence Shows | Typical Timeline to See Results | Reversibility if Stopped |
|---|---|---|---|---|---|
| Finasteride | Type II 5-alpha-reductase inhibitor taken orally by prescription | FDA-approved for male pattern hair loss in men3 | Placebo-controlled trials found improved scalp hair at one and two years. One small, open-label trial with unequal groups favored finasteride over topical minoxidil, but it does not provide definitive comparative proof.1,5 | The FDA label states that three months or more of daily use is generally needed before benefit is observed.3 | The effect reverses within about 12 months after treatment is withdrawn.3 |
| Minoxidil | Topical over-the-counter treatment. Oral minoxidil is a separate, off-label prescription use. | Topical 5% minoxidil is labeled for regrowth on the vertex or crown. Oral minoxidil is not FDA-approved for hair loss.4 | Topical 5% minoxidil outperformed topical 2% minoxidil and placebo after 48 weeks. Oral trials have not shown superiority over topical 5% minoxidil.6,9,10 | The topical label states that results may appear around two months. Some men need at least four months before seeing results.4 | Continued topical use is needed to maintain regrowth. Hair loss begins again after treatment stops.4 |
If you are still assessing whether your hair has changed, review the first signs of hair loss before comparing prescriptions. A treatment decision becomes more useful once you and your physician have identified the pattern you are tracking.
Different Mechanisms Behind Each Treatment
Finasteride inhibits type II 5-alpha-reductase, an enzyme that converts testosterone into DHT. This lowers DHT in the scalp and blood.1 The broader biology and treatment categories are covered in our guide to DHT blockers.
Minoxidil acts through a different pathway. Topical minoxidil appears to shorten the resting phase of the hair cycle and prompt follicles to enter the growth phase earlier. It may also enlarge hair follicles.2
Minoxidil is often described as a potassium-channel opener, but that proposed hair-growth mechanism has not been clearly demonstrated in human hair follicles.2 Your prescriber does not need a fully settled molecular explanation to use the clinical trial results. The treatment decision rests on observed outcomes, route, safety, and your response over time.
Direct Evidence in the Finasteride vs Minoxidil Comparison
The only true direct comparison was a 12-month trial that assigned 40 participants to oral finasteride and 25 to topical 5% minoxidil. The authors reported clinical cure rates of 80% for finasteride and 52% for minoxidil.5
That directional result deserves context. The trial was small, open-label, and split participants into unequal groups. Participants and investigators knew which treatment was being used, so subjective clinical assessments could have been influenced by treatment expectations.
The direct trial supports considering finasteride as an effective option. It does not establish that finasteride will outperform minoxidil for every person. A larger blinded comparison with balanced groups could strengthen or change confidence in that relative finding.
Each treatment also has its own placebo-controlled evidence base. Two finasteride trials included 1,553 men ages 18 to 41. Oral finasteride improved scalp hair across the study evaluations at one year and two years compared with placebo.1
A separate minoxidil trial included 393 men ages 18 to 49. After 48 weeks, topical 5% minoxidil outperformed topical 2% minoxidil and placebo. It also caused more itching and local irritation than the 2% solution.6
Those placebo-controlled trials establish that each drug can work. Because they tested different participants under separate protocols, they cannot provide a clean ranking between treatments. Your prescriber can weigh those results alongside the small direct trial without treating any single study as the entire answer.
Finasteride Side Effects in the Clinical Evidence
Finasteride can cause sexual side effects, but the absolute trial rates were low. In the first year of the FDA registration trials, decreased libido was reported by 1.8% of participants taking finasteride and 1.3% taking placebo. Erectile dysfunction was reported by 1.3% and 0.7%, respectively.3
Across the sexual adverse experiences listed in the label, 3.8% of participants taking finasteride reported at least one event, compared with 2.1% taking placebo. The label states that symptoms resolved in men who stopped treatment and in many men who continued. Rates for each listed event declined to 0.3% or lower by year five.3
A meta-analysis of randomized controlled trials found a relative risk of 1.66 for sexual dysfunction with finasteride compared with placebo, with a 95% confidence interval from 1.20 to 2.30.7 Relative risk describes the difference between groups. It does not replace the absolute rates when you are weighing your personal risk.
Persistent symptoms have also been reported. One interview study recruited 71 men who already reported sexual symptoms lasting at least three months after stopping finasteride. Within that selected group, 94% reported low libido and 92% reported erectile dysfunction. The reported mean duration of persistent symptoms was 40 months.8
That study had no control group and did not recruit a general population of finasteride users. Its percentages describe a small, self-selected symptomatic group, so they cannot estimate overall incidence. Bring both the controlled trial rates and the persistent-symptom report into your consultation so your prescriber can assess the evidence against your medical history and priorities.
Oral and Topical Minoxidil Evidence
Oral minoxidil for hair loss is an off-label use of an older oral drug. It is a separate route that requires prescribing and medical review. It has not been shown to be a superior replacement for topical minoxidil.
A 2024 randomized trial compared oral minoxidil studied at 5 mg once daily with topical 5% minoxidil studied twice daily over 24 weeks. Among 68 participants who completed the trial, oral minoxidil did not outperform topical minoxidil on the primary outcomes.9
Hypertrichosis, meaning increased hair growth outside the intended scalp area, affected 22 of 45 participants in the oral group. Headache affected 6 of 45 participants.9 These were results from the studied trial regimen, not dosing guidance.
A second 2024 randomized trial compared oral minoxidil studied at 1 mg with topical minoxidil. Topical treatment had a better overall therapeutic effect, but the difference between groups was not statistically clear.10
Oral minoxidil gives your prescriber another route to consider when topical treatment presents practical or tolerance problems. Current comparative evidence supports treating it as another option to weigh rather than an efficacy upgrade.
Evidence for Combination Therapy
Finasteride and topical minoxidil can be used together under clinical direction. The combination targets DHT production and the follicle cycle through separate pathways.
A meta-analysis of five randomized controlled trials found that combination therapy produced better global photographic and categorical improvement than either treatment alone. The safety profile was similar across groups. The analysis did not find a clear difference in hair-density change specifically.11
Combination therapy may make sense when your prescriber wants to address both pathways. Follow-up still needs to separate tolerability, consistency, and response so the plan can be adjusted with a clear reason.
The Opt Take on Hair-Loss Treatment
Hair-loss treatment works best as an adjusted plan with a defined baseline and regular review. A product comparison can show how finasteride and minoxidil differ. Your response determines whether the first plan remains appropriate.
At Opt Health, a physician reviews your symptoms, current medications, health data, and goals before building a treatment plan. Follow-up then examines what changed after treatment began. The prescription is one part of that loop.
A useful follow-up addresses several distinct questions:
- Elapsed time: Your prescriber compares the treatment period with the timeline reported in the FDA label before judging the response.
- Consistency: If topical use has been difficult to maintain, your prescriber can address the route before concluding that minoxidil did not work.
- Side effects: New sexual symptoms, scalp irritation, headache, or unwanted hair growth can change the balance between benefit and tolerability.
- Hair pattern: Continued thinning at the crown or hairline may change how your prescriber interprets the response and the label limitations.
If hair loss appears to continue, your prescriber can check whether enough time has passed and whether the original pattern remains the same. A route that does not fit your daily routine also changes the next step, even when the clinical evidence supports the drug.
Side-effect feedback carries equal weight. A physician may continue observation, change the route, reconsider one part of a combination, or discuss another treatment based on your response. The plan follows the pattern over time through review, treatment, reassessment, and adjustment.
Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.
Frequently Asked Questions
Yes, finasteride and topical minoxidil can be used together under clinical direction. A meta-analysis of five randomized trials found better photographic and categorical improvement with combination therapy than with either treatment alone. Safety was similar, although hair-density change did not clearly differ.11 Your prescriber can decide whether targeting both pathways fits your treatment history and side-effect priorities.
Topical minoxidil may produce visible results sooner according to the FDA labels. Minoxidil results may appear around two months, although some men need at least four months. Finasteride generally requires three months or more before benefit is observed.3,4 These timelines set reasonable follow-up points, not a forecast of which drug will regrow more hair for you. Bring what you see at each point back to your prescriber so the plan can be adjusted with real information.
The benefits of both treatments depend on continued use. The finasteride label states that its effect reverses within about 12 months after withdrawal. The topical minoxidil label states that hair loss begins again after treatment stops.3,4 If you are considering stopping either treatment, your prescriber can explain the expected change and plan the next review.
Current randomized trials have not shown oral minoxidil to be better than topical minoxidil. A 2024 trial studying oral minoxidil at 5 mg found no superiority over topical 5% minoxidil on its primary outcomes.9 A smaller trial studying oral minoxidil at 1 mg also found no clear difference.10 Oral minoxidil remains an off-label route that your prescriber may weigh against the established topical option.
Finasteride side effects can include decreased libido and erectile dysfunction. In FDA trials, decreased libido occurred in 1.8% of the finasteride group and 1.3% of the placebo group. Erectile dysfunction occurred in 1.3% and 0.7%, respectively.3 Persistent symptoms have been reported in a small self-selected study, but that study cannot estimate population-wide risk.8 Discuss new symptoms with your prescriber so they can be evaluated in context.
Topical 5% minoxidil has a specific label limitation by scalp location. The FDA label covers regrowth on the vertex or crown and states that the product is not intended for frontal baldness or a receding hairline.4 Finasteride trials did not apply that same vertex-only label restriction, but the evidence does not establish a guaranteed hairline response.1 Use your exact pattern in the finasteride vs minoxidil discussion with your prescriber.
References
- Kaufman KD, Olsen EA, Whiting D, et al.; Finasteride Male Pattern Hair Loss Study Group. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589. https://pubmed.ncbi.nlm.nih.gov/9777765/
- Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186-194. https://pubmed.ncbi.nlm.nih.gov/14996087/
- Organon LLC. PROPECIA (finasteride) tablets: full prescribing information. U.S. Food and Drug Administration. Revised July 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020788s030lbl.pdf
- McNeil-PPC, Inc. Men’s ROGAINE Extra Strength (minoxidil 5% w/v topical solution): OTC Drug Facts label. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020834Orig1s014lbl.pdf
- Arca E, Açikgöz G, Taştan HB, Köse O, Kurumlu Z. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology. 2004;209(2):117-125. https://pubmed.ncbi.nlm.nih.gov/15316165/
- Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385. https://pubmed.ncbi.nlm.nih.gov/12196747/
- Lee S, Lee YB, Choe SJ, Lee WS. Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis. Acta Derm Venereol. 2019;99(1):12-17. https://pubmed.ncbi.nlm.nih.gov/30206635/
- Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747-1753. https://pubmed.ncbi.nlm.nih.gov/21418145/
- Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: a randomized clinical trial. JAMA Dermatol. 2024;160(6):600-605. https://pubmed.ncbi.nlm.nih.gov/38598226/
- Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled trial. J Cosmet Dermatol. 2024;23(3):949-957. https://pubmed.ncbi.nlm.nih.gov/38031516/
- Chen L, Zhang J, Wang L, Wang H, Chen B. The efficacy and safety of finasteride combined with topical minoxidil for androgenetic alopecia: a systematic review and meta-analysis. Aesthetic Plast Surg. 2020;44(3):962-970. https://pubmed.ncbi.nlm.nih.gov/32166351/
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.